ALK and non-small cell lung carcinoma: Similarly, in mesenchymal non-small-cell lung cancer cell lines with EMT features, resistance to erlotinib and upregulation of AXL was associated with markedly increased levels of GAS6.16, 17 Therefore, cleaved soluble GAS6 could be exploited as a biomarker of resistance to ALK inhibition.